The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com.
About us
Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create #MoreMoments for the neurodegenerative disease community. Community Guidelines: https://bit.ly/3C1v1wz Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.
- Website
-
http://www.amylyx.com
External link for Amylyx Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Specialties
- ALS, Neurodegenerative Diseases, and Amyotrophic Lateral Sclerosis
Locations
-
Primary
Get directions
Cambridge, MA 02141, US
Employees at Amylyx Pharmaceuticals
Updates
-
Today, we announced the acquisition of an investigational, Phase 3-ready GLP-1 receptor antagonist for the potential treatment of hyperinsulinemic hypoglycemia. We look forward to studying this new scientific pathway, building on our endocrine and neuroscience expertise, and advancing our mission to bring new therapies forward for communities with unmet needs. Read more: https://lnkd.in/dR2C2jef
-
Amylyx’ Evan Mizerak is presenting data from our preclinical program in #ALS at the Oligonucleotides for CNS Summit in Boston this week. More details below.
-
-
Our work is far from over, and we will not stop discovering, developing, and advocating on behalf of the ALS community who urgently need new treatment options. Every day reinforces our commitment to discover and develop more treatment options for those suffering from ALS and other #neurodegenerative diseases.
-
-
#DYK common symptoms of #Wolframsyndrome include juvenile diabetes mellitus, optic atrophy, and deafness. Learn more about the causes and symptoms that affect those living with Wolfram.
-
We’re excited to be at #ENCALS2024 to share more about our work in #ALS and learn from others who share our mission of one day ending the suffering caused by #neurodegenerativediseases. More details below.
-
Congratulations to Irene Aquino, our Head of Global Patient and Professional Advocacy, for being nominated as a Rare Champion of Industry. Thank you for the passion with which you embrace Amylyx’ mission and for keeping people living with rare diseases and their families at the center of all that you do!
Introducing the nominees for the 2024 RARE Champions of Hope! ✨ We extend our heartfelt congratulations to all nominees. Stay tuned as we reveal and honor the winners at the highly anticipated 2024 RARE Champions of Hope Celebration during Week in RARE. #WeekinRARE #ChampionsofHope #ChampionsofHope2024 #RAREAdvocacySummit #CareAboutRare #PatientAdvocacy #GlobalGenes #RAREX #RAREChampionsofHope #RareChampions #RareDisease #RareAdvocacy #RareHealthEquity #RareIndustry #RareResearch #RareDiseaseAward
-
Today in the U.S., we honor and remember the men and women of our military who have served our nation. Many veterans are living with diseases like ALS and MS, or with spinal cord injuries and disorders. As we reflect on their selfless service, we express our gratitude to all those who dedicated their lives to our country, including those impacted by ALS.
-
Check out Amylyx’ Evan Mizerak and Charles River’s discussion of the use of ASOs in ALS research and learn more about how ASOs are developed below. ⬇
Antisense oligonucleotides (ASOs) an emerging drug modality that is having clinical impact in neurological and rare diseases, including ALS/Motor Neuron Disease. In this webinar experts from Amylyx Pharmaceuticals and Charles River discuss design and screening of ASO, and considerations for designing successful in vivo efficacy studies. https://okt.to/tFBCK5